Another milestone for AC Immune

Please login or
register
24.07.2015

AC Immune receives a milestone payment from Genentech for a phase III clinical development.

Lausanne-based AC Immune has announced that its partner Genentech, a member of the Roche Group, is to move crenezumab into phase III clinical development in people with prodromal-to-mild Alzheimer’s disease. Under the terms of the agreement, AC Immune will receive an undisclosed milestone payment.

Crenezumab was discovered by AC Immune using its SupraAntigen technology platform and out-licensed to Genentech in 2006 as a potential therapy for Alzheimer’s disease. In 2012 it was chosen by an international panel of experts, which included the US National Institutes of Health, for use in a first prevention trial in Alzheimer’s disease in a large extended family in Colombia.

In 2006 AC Immune signed a research collaboration and out-licensing agreement for its anti-Abeta antibody program with Genentech, under which Genentech develops crenezumab for the treatment of Alzheimer´s disease. Genentech has full control and global responsibility for clinical development, manufacturing and commercialization of the antibody. In return, AC Immune received an upfront payment and three milestone payments.

0Comments

More news about

AC Immune SA

Company profiles on startup.ch

AC Immune SA

rss